BiomX Inc. Files 8-K for "Other Event"
Ticker: PHGE · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1739174
| Field | Detail |
|---|---|
| Company | Biomx Inc. (PHGE) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, other-event
TL;DR
BiomX filed an 8-K for an 'Other Event' on Dec 16. Details TBD.
AI Summary
BiomX Inc. filed an 8-K on December 16, 2024, reporting an "Other Event." The filing does not contain specific details about the event itself, but it confirms the company's reporting status and principal executive offices in Ness Ziona, Israel.
Why It Matters
This filing indicates a material event has occurred for BiomX Inc., requiring disclosure to investors, though the specific nature of the event is not detailed in this summary.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for an 'Other Event' without immediate disclosed financial impact or significant operational changes.
Key Players & Entities
- BiomX Inc. (company) — Registrant
- Chardan Healthcare Acquisition Corp. (company) — Former company name
- December 16, 2024 (date) — Date of earliest event reported
FAQ
What specific event is BiomX Inc. reporting in this 8-K filing?
The provided text for the 8-K filing indicates an 'Other Event' but does not specify the nature of the event.
When was this 8-K filing submitted?
The filing was submitted on December 16, 2024.
What is BiomX Inc.'s principal executive office address?
BiomX Inc.'s principal executive offices are located at 22 Einstein St., Floor 4, Ness Ziona, Israel, 7414003.
What was BiomX Inc.'s former company name?
BiomX Inc.'s former company name was Chardan Healthcare Acquisition Corp., with a name change date of April 30, 2018.
What is the company's standard industrial classification?
The company's Standard Industrial Classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Filing Stats: 700 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2024-12-16 09:32:53
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value PHGE NYSE American Indi
Filing Documents
- ea0224867-8k_biomx.htm (8-K) — 24KB
- 0001213900-24-109057.txt ( ) — 193KB
- phge-20241216.xsd (EX-101.SCH) — 3KB
- phge-20241216_lab.xml (EX-101.LAB) — 33KB
- phge-20241216_pre.xml (EX-101.PRE) — 22KB
- ea0224867-8k_biomx_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On December 16, 2024, BiomX Inc. (the "Company") announced that on December 10, 2024, it received a notice from the New York Stock Exchange that the Company had regained compliance with all NYSE American LLC ("NYSE American") continued listing standards. Specifically, the Company has resolved prior listing deficiencies raised on May 23, 2024, by NYSE American and set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide. NYSE American confirmed that the Company has demonstrated compliance with the continued listing standard for a period of two consecutive quarters pursuant to Section 1009(f) of the Company Guide. Safe Harbor This Current Report on Form 8-K contains express or implied "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, the Company is making forward-looking are neither historical facts nor assurances of future performance. Instead, they are based only on Company management's current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Sec